OverviewSuggest Edit

XBiotech is a biosciences company dedicated to the discovery, development, and commercialization of therapeutic antibodies based on its True Human technology. Its technology allows the identification of the unique genetic information of immune antibodies from donor blood. This genetic information is used for the production of antibody therapies without modification. The company targets oncology, inflammatory conditions, and infectious diseases.
TypePublic
Founded2005
HQAustin, TX, US
Websitexbiotech.com
Employee Ratings2.9

Latest Updates

Employees (est.) (Mar 2020)60(+4%)
Revenue (FY, 2020)$44 M
Share Price (Jun 2021)$17
Cybersecurity ratingCMore

Key People/Management at XBiotech

John Simard

John Simard

Founder, President, Chief Executive Officer & Chairman
Sushma Shivaswamy

Sushma Shivaswamy

Chief Scientific Officer
Qian Wu

Qian Wu

Vice President of Quality Control
Norma I. Gonzalez

Norma I. Gonzalez

Vice President of Quality
Ashley Otero

Ashley Otero

Vice President of Clinical Operations
Queena Han

Queena Han

Vice President of Finance and Human Resources
Show more

XBiotech Office Locations

XBiotech has an office in Austin
Austin, TX, US (HQ)
5217 Winnebago Ln
Show all (1)

XBiotech Financials and Metrics

XBiotech Revenue

XBiotech's revenue was reported to be $44 m in FY, 2020
USD

Revenue (Q1, 2021)

4.9m

Gross profit (Q1, 2021)

2.5m

Gross profit margin (Q1, 2021), %

52.5%

Net income (Q1, 2021)

(2.6m)

EBIT (Q1, 2021)

(3.6m)

Market capitalization (4-Jun-2021)

508.2m

Closing stock price (4-Jun-2021)

17.0

Cash (31-Mar-2021)

239.9m
XBiotech's current market capitalization is $508.2 m.
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Revenue

44.0m

Cost of goods sold

34.5m

Gross profit

9.4m

Gross profit Margin, %

21%
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

12.7m15.5m10.5m4.9m

Cost of goods sold

9.7m13.2m9.4m2.3m

Gross profit

3.0m2.3m1.1m2.5m

Gross profit Margin, %

24%15%11%52%
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Cash

31.8m15.8m714.6m237.4m

Accounts Receivable

4.1m

Prepaid Expenses

1.6m1.2m1.7m582.0k

Current Assets

33.3m17.0m716.3m325.9m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

28.4m24.8m20.8m12.0m44.9m40.3m241.5m229.7m238.4m239.9m

Accounts Receivable

9.7m20.7m6.1m1.7m

Prepaid Expenses

1.3m917.0k457.0k963.0k678.0k573.0k1.2m802.0k439.0k6.3m

Current Assets

29.7m25.8m21.3m13.0m45.6m40.9m257.9m258.4m251.7m327.9m
Annual
USDFY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(33.1m)(21.1m)668.6m(11.2m)

Depreciation and Amortization

1.5m2.4m2.4m2.2m

Accounts Payable

(2.7m)(78.0k)496.0k(334.0k)

Cash From Operating Activities

(33.6m)(16.5m)(18.3m)(65.1m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(4.1m)(10.0m)(15.0m)(5.9m)(11.7m)(17.9m)(14.0k)(6.9m)(9.4m)(2.6m)

Depreciation and Amortization

588.0k1.2m1.8m602.0k1.2m1.8m558.0k1.1m1.7m621.0k

Accounts Payable

(596.0k)(275.0k)(853.0k)99.0k(212.0k)(592.0k)3.5m3.1m542.0k(1.4m)

Cash From Operating Activities

(3.5m)(7.4m)(11.4m)(4.7m)(9.5m)(14.5m)(60.7m)(72.2m)(64.8m)1.8m
USDFY, 2017

Financial Leverage

1 x
Show all financial metrics

XBiotech Cybersecurity Score

Cybersecurity ratingPremium dataset

C

77/100

SecurityScorecard logo

XBiotech Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

XBiotech Online and Social Media Presence

Embed Graph

XBiotech News and Updates

French National Cancer Institute and XBiotech Join forces to Conduct Innovative Phase II/III Adaptive Multicenter Clinical Study for XBiotech’s New Cancer Drug for Colorectal Cancer

XBiotech to Supply INSERM its New Drug to Use in Combination Therapy for Treating Advanced Colorectal Cancer XBiotech to Supply INSERM its New Drug to Use in Combination Therapy for Treating Advanced Colorectal Cancer

XBiotech Candidate True Human™ COVID-19 Therapy Found to Target Highly Infectious Emerging Strain

XBiotech Inc. (NASDAQ: XBIT) announces that its COVID-19 candidate True Human™ antibody therapy may also be used for treating the COVID-19 mutant virus that recently emerged in the UK and is now rapidly spreading across the US. The mutant COVID-19 virus has alterations to the spike protein that repo…

XBiotech Announces Cerebrovascular Medical Advisory Board & Development of New Stroke Therapy

XBiotech Inc. (NASDAQ: XBIT) announced today the first meeting of its Cerebrovascular Medical Advisory Board (CMAB). The CMAB is comprised of key opinion leaders who specialize in cerebrovascular diseases including ischemic stroke, which is the third leading cause of death and second leading cause o…

XBiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influenza-COVID-19 Therapeutic Cocktail

XBiotech Inc. (NASDAQ: XBIT) announced today new data for its breakthrough candidate therapy for treating infections of influenza and COVID-19. The Company continues to analyze components of its so-called FLUVID™ therapy as it develops manufacturing capability for a product candidate.

XBiotech Developing True Human Antibody Combination as Candidate Treatment for Influenza-COVID-19 Co-Infections

XBiotech Inc. (NASDAQ: XBIT) announced today it is developing a new breakthrough candidate therapy it calls FLUVID™ for treating illness caused by combined infections with influenza and COVID-19. With the global spread of the novel COVID-19 virus, there will be added risk during flu seasons that peo…

XBiotech Achieves Milestone for Production of its New Potential Blockbuster Anti-IL-1⍺ Therapy

XBiotech Inc. (NASDAQ: XBIT) announced today it has achieved a crucial milestone in the development of its next generation inflammation-fighting True Human antibodies. The Company is developing a new antibody to replace a previous generation True Human anti-IL-1⍺ antibody that was sold in 2019 for $…
Show more

XBiotech Blogs

XBiotech Data Shows Effective Anti-Virus Activity for True Human Antibodies in Its Candidate Influenza-COVID-19 Therapeutic Cocktail

Candidate Therapy for Flu+Covid-19 Co-infection Shows Potent Anti-Viral Potential AUSTIN, Texas , Nov. 19, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today new data for its breakthrough candidate therapy for treating infections of influenza and COVID-19.

XBiotech-Developed COVID-19 Test Supports Convalescent Blood Treatments Now Approved Under FDA Emergency Use Authorization

FDA has Authorized Use of Antibody-Rich COVID-19 Therapy Derived from Convalescent Patients Under Collaboration BioBridge Global Will Be Using XBiotech’s COVID-19 Antibody Test to Identify the Convalescent Blood Products AUSTIN, Texas , Aug. 24, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc.

XBiotech Discovers COVID-19 Candidate Therapy

The Company has Identified Highly Targeted Anti-COVID-19 True Human Antibodies from Immune Donor Blood AUSTIN, Texas , Aug. 17, 2020 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) announced today that it has identified True Human antibodies that could potentially be used as a therapy against

MIKE CAVALIER PH.D.

MIKE CAVALIER PH.D. Michaela.Delmo… Wed, 06/03/2020 - 06:24 MIKE CAVALIER PH.D. Director of Manufacturing As a Ph.D. level Protein Biochemist with Postdoctoral training and relevant biotech experience, Dr. Cavalier oversees all aspects o…

ASHLEY OTERO

ASHLEY OTERO Michaela.Delmo… Wed, 06/03/2020 - 06:24 ASHLEY OTERO Vice President of Clinical Operations Ms. Otero joined XBiotech in June 2009. She currently serves as Vice President of Clinical Operations where she has successfully led t…

QIAN WU PH.D.

QIAN WU PH.D. Michaela.Delmo… Wed, 06/03/2020 - 06:24 QIAN WU PH.D. Vice President of Quality Control Dr. Wu has served XBiotech as VP of Quality Control since July 2017. She oversees quality control function to support CMC and clinical o…
Show more

XBiotech Frequently Asked Questions

  • When was XBiotech founded?

    XBiotech was founded in 2005.

  • Who are XBiotech key executives?

    XBiotech's key executives are John Simard, Sushma Shivaswamy and Qian Wu.

  • How many employees does XBiotech have?

    XBiotech has 60 employees.

  • What is XBiotech revenue?

    Latest XBiotech annual revenue is $44 m.

  • What is XBiotech revenue per employee?

    Latest XBiotech revenue per employee is $733.3 k.

  • Who are XBiotech competitors?

    Competitors of XBiotech include Praxis Precision Medicines, Aptinyx and RAPT Therapeutics.

  • Where is XBiotech headquarters?

    XBiotech headquarters is located at 5217 Winnebago Ln, Austin.

  • Where are XBiotech offices?

    XBiotech has an office in Austin.

  • How many offices does XBiotech have?

    XBiotech has 1 office.